about
The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature ReviewPerceptions and Barriers of Survivorship Care in Asia: Perceptions From Asian Breast Cancer Survivors.Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in SingaporeClinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future researchClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort studyRoutine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP ChemotherapyImpact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients.Survey of topical oral solutions for the treatment of chemo-induced oral mucositis.Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.Medication use by early-stage breast cancer survivors: a 1-year longitudinal study.Drug interactions between chemotherapeutic regimens and antiepileptics.Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and VomitingClinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies.Polypharmacy in elderly patients with cancer: clinical implications and management.Neuro-cognitive impairment in breast cancer patients: pharmacological considerations.Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.Clinically-relevant anticancer-antidepressant drug interactions.An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors.Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies.Minimum qualifications for clinical pharmacy practice faculty.Management options for established chemotherapy-induced peripheral neuropathy.Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy.Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials.2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.Carotid artery inflammation associated with gemcitabine-based therapy: a special report.Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients.Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCell Lymphoma: an Observational Study.Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI.OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions.Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines.Feasibility and acceptance of a pharmacist-run tele-oncology service for chemotherapy-induced nausea and vomiting in ambulatory cancer patients.
P50
Q28550429-468CCE8F-7397-490D-A7FE-F9BD478BE537Q33859799-F48D53EF-E295-4798-96EE-012E434DE617Q34677539-621B0D33-B670-44F6-9E61-69327A6B8B5AQ34940071-5CE46E5E-4AB4-4699-B0AA-A895F6928139Q35023711-316BAE5D-F717-46E2-B2F9-23EF73C776F6Q35067446-47CE6EB8-F552-4BB7-AEC0-B31D685A7770Q35083960-3B580C47-EB5D-4EAC-AF04-4A590F31FB7EQ35775258-E98C540A-651C-4F94-B83B-89298BDC1509Q35922123-8D93FA33-1725-48A5-974A-92810B541690Q36152838-201DC88C-58A3-408D-8327-C267265ED5ADQ36440613-D917183C-799C-4AFB-9FAB-2CCDCE964709Q36478194-2BEF8885-4EC1-4C33-8C76-6F7C0DD76827Q36493824-92B69235-D386-41EC-9D5D-7C7F3FD81FE5Q36615005-51591BF1-0112-47E2-92BC-85B8721C626FQ37274036-89D9815E-E832-4ABC-AFF0-0AACF138C252Q37326382-EDC0ABC1-5F24-4A7F-AA9E-87BE51E77793Q37334707-B5143CF2-16A1-4B7D-9C15-6D7770BB613EQ37597811-A03334A2-5037-4480-84E1-9045033905E0Q37856534-CC4267BE-A5A0-4512-9FF7-1840CA83FA59Q37899374-6A5D61D7-515F-45B7-BAC5-C02B3DAC3289Q37947927-05A47B9B-38AC-46BA-A0E7-DB502A62CBCFQ37966017-A6C95121-E77E-4A7C-8626-C77E2638F53BQ37970709-AAE197A7-5C56-4B53-A9E5-B65F5ACE979CQ38000038-09A11319-3E57-435F-AEF9-BB023F2D0B1EQ38127801-F39DFAE9-68DA-47D1-BBB1-C168B7D01A0EQ38216036-D3B3F664-E3A0-43AE-8619-F58F4697C9F9Q38216217-F5C8BB27-6F49-46A7-A208-81954050752AQ38268600-E18D78BF-CCE2-442C-899F-81DBF9031C8CQ38323964-331478E7-471A-49B2-A092-B0EC6719917CQ38631642-CFA105D6-86F8-4B9B-9B81-A8C4B43E3D60Q38638873-1248DFE4-3323-4D49-A98C-4FB90BDF9CC7Q38904462-BEF759DF-ADC9-4A0B-88C0-9CB7F569B30AQ38982287-DD353E17-9EA0-4EC0-8BFB-F71DB46D1BAAQ39048761-F177CF55-BD57-47E3-A72D-E17B6592AA56Q39225496-1320E976-227C-41E6-91D0-156607D22BE1Q39503463-DD37E2D8-6D0F-4631-8CD0-B2CCDB8213A1Q39716729-82DEB1F6-EA0A-4E8E-A0DB-F4F0F0ED7E19Q39898909-3126A9F6-6411-40D7-B38C-CB9096FD0CBBQ40020379-41DC7E33-1EB8-426A-9262-5080F59F43F5Q40100881-FAA405DE-47EB-44D5-8EDB-D75A7B13F9B4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alexandre Chan
@ast
Alexandre Chan
@en
Alexandre Chan
@es
Alexandre Chan
@nl
Alexandre Chan
@sl
type
label
Alexandre Chan
@ast
Alexandre Chan
@en
Alexandre Chan
@es
Alexandre Chan
@nl
Alexandre Chan
@sl
prefLabel
Alexandre Chan
@ast
Alexandre Chan
@en
Alexandre Chan
@es
Alexandre Chan
@nl
Alexandre Chan
@sl
P106
P1153
21739137300
P21
P31
P496
0000-0003-4391-4219